13F reference period
Q2 2026
Security Snapshot
Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share (KLRS) Institutional Ownership
CUSIP: 482929106
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
55
Shares (Excl. Options)
18.03M
Full value: 18,030,969 · shares · 30 Jun 2026Price
$4.07
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- KLRS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 18,030,969
- Total 13F value
- $73,385,261
- Portfolio coverage rank
- 0%
- Share change
- -547,099
- Value change
- -$4,541,862
- Number of holders
- 55
- Shares outstanding
- 23,815,800
- SEC-reported price per share
- $2.89
- Insider filing price
- $2.89
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- KLRS - Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 482929106.
- 55 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 57 to 55 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$107.18M
Full value: $107,183,840 · USD · 31 Mar 2026.$73.39M
Full value: $73,385,261 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 55 institutions filings for Q2 2026.
Security key
482929106
13F reference period
Q2 2026
13F holders
55
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
KLRS full holder history
Kalaris Therapeutics, Inc. SEC filings
Kalaris Therapeutics, Inc. company facts
Kalaris Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482929106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
KLRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 54% | -4% | $85,014,842 | -$349,257 | 12,900,583 | -0.41% | Srinivas Akkaraju | 20 May 2026 |
| Coastlands Capital LP | 5.7% | $3,916,158 | 1,355,119 | Coastlands Capital LP | 19 Oct 2026 | |||
| RTW INVESTMENTS, LP | 5.7% | $12,714,000 | 1,300,000 | RTW Investments, LP | 31 Dec 2025 | |||
| GILEAD SCIENCES, INC. | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | |||
| Invus Global Management, LLC | 1.5% | $754,533 | 282,586 | Invus Public Equities, L.P. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 1.1% | $1,315,201 | 201,718 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 30 Jun 2026,
55
institutional investors reported holding
shares of
Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share (KLRS).
This represents
76%
of the company’s total
outstanding shares.
18.03M
Full value: 18,030,969 · shares · 30 Jun 202623.82M
Full value: 23,815,800 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 54% | 12,881,175 | -0.52% | 4.3% | $52,426,382 |
| RTW INVESTMENTS, LP | 5.5% | 1,300,000 | 0% | 0.05% | $5,291,000 |
| Alyeska Investment Group, L.P. | 2.4% | 572,687 | 0% | 0.01% | $2,330,836 |
| Siren, L.L.C. | 1.8% | 435,798 | 0% | 0.04% | $1,773,698 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 398,712 | +56% | 0% | $1,622,758 |
| Ikarian Capital, LLC | 1.5% | 360,000 | 0% | 0.24% | $1,465,201 |
| UBS Group AG | 1.1% | 262,131 | +4139% | 0% | $1,066,873 |
| RENAISSANCE TECHNOLOGIES LLC | 0.63% | 149,351 | +126% | 0% | $607,859 |
| MARSHALL WACE, LLP | 0.58% | 139,201 | +105% | 0% | $566,549 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.48% | 114,037 | +30% | 0% | $464,287 |
| Woodline Partners LP | 0.42% | 100,000 | 0% | 0% | $407,000 |
| ADAR1 Capital Management, LLC | 0.42% | 100,000 | 0% | 0.02% | $407,000 |
| WHI TRUST Co LLC | 0.41% | 97,493 | 0% | 0.26% | $396,797 |
| RAYMOND JAMES FINANCIAL INC | 0.41% | 97,164 | -18% | 0% | $395,457 |
| CITADEL ADVISORS LLC | 0.4% | 95,772 | 0% | $389,792 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.39% | 92,261 | 0% | 0.01% | $375,502 |
| Verdad Advisers, LP | 0.34% | 80,297 | 0.31% | $326,809 | |
| MORGAN STANLEY | 0.3% | 72,326 | +89% | 0% | $294,367 |
| VANGUARD FIDUCIARY TRUST CO | 0.28% | 66,179 | +80% | 0% | $269,349 |
| BlackRock, Inc. | 0.23% | 54,442 | +51% | 0% | $221,580 |
| Belpointe Asset Management LLC | 0.17% | 40,000 | 0% | 0.01% | $162,800 |
| Fortis Capital Advisors, LLC | 0.17% | 40,000 | 0% | 0.02% | $162,800 |
| Pale Fire Capital SE | 0.17% | 39,626 | 0.01% | $161,278 | |
| Squarepoint Ops LLC | 0.16% | 38,775 | -2.5% | 0% | $157,814 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.14% | 32,500 | +44% | 0% | $132,275 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 118,694 | $343,139 | -$133,881 | $2.89 | 5 |
| 2026 Q2 | 18,030,969 | $73,385,261 | -$4,541,862 | $4.07 | 55 |
| 2026 Q1 | 18,578,668 | $107,183,840 | +$2,867,539 | $5.77 | 57 |
| 2025 Q4 | 17,996,162 | $151,883,912 | +$39,427,360 | $8.44 | 51 |
| 2025 Q3 | 13,222,873 | $76,428,251 | +$1,455,559 | $5.78 | 31 |
| 2025 Q2 | 13,362,268 | $35,677,274 | -$2,639,077 | $2.67 | 29 |
| 2025 Q1 | 13,874,350 | $111,411,096 | +$111,410,076 | $8.03 | 31 |